Research programme: oncolytic virus therapies - Wellstat Biologics

Drug Profile

Research programme: oncolytic virus therapies - Wellstat Biologics

Alternative Names: PV 327; PV 674; PV 839; PV 921

Latest Information Update: 29 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Wellstat Biologics Corporation
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Leukaemia; Solid tumours

Most Recent Events

  • 29 Jun 2017 Research programme: oncolytic virus therapies - Wellstat Biologics is still in preclinical development for solid tumours and leukaemia in USA (Wellstat Biologics pipeline, June 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Leukaemia in USA (IV)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top